JP6023061B2 - ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用 - Google Patents

ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用 Download PDF

Info

Publication number
JP6023061B2
JP6023061B2 JP2013532945A JP2013532945A JP6023061B2 JP 6023061 B2 JP6023061 B2 JP 6023061B2 JP 2013532945 A JP2013532945 A JP 2013532945A JP 2013532945 A JP2013532945 A JP 2013532945A JP 6023061 B2 JP6023061 B2 JP 6023061B2
Authority
JP
Japan
Prior art keywords
polypeptide
rsv
seq
antibody
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013532945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502143A5 (enExample
JP2014502143A (ja
Inventor
アール． シーフ、ウィリアム
アール． シーフ、ウィリアム
イー． コレイア、ブルーノ
イー． コレイア、ブルーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of JP2014502143A publication Critical patent/JP2014502143A/ja
Publication of JP2014502143A5 publication Critical patent/JP2014502143A5/ja
Application granted granted Critical
Publication of JP6023061B2 publication Critical patent/JP6023061B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013532945A 2010-10-06 2011-10-06 ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用 Expired - Fee Related JP6023061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39059110P 2010-10-06 2010-10-06
US61/390,591 2010-10-06
PCT/US2011/055113 WO2012048115A2 (en) 2010-10-06 2011-10-06 Polypeptides and their use in treating and limiting respiratory syncytial virus infection

Publications (3)

Publication Number Publication Date
JP2014502143A JP2014502143A (ja) 2014-01-30
JP2014502143A5 JP2014502143A5 (enExample) 2014-10-30
JP6023061B2 true JP6023061B2 (ja) 2016-11-09

Family

ID=44993163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532945A Expired - Fee Related JP6023061B2 (ja) 2010-10-06 2011-10-06 ポリペプチド、ならびに呼吸器多核体ウイルス感染症の治療および制限における該ポリペプチドの使用

Country Status (7)

Country Link
US (1) US9718862B2 (enExample)
EP (1) EP2625194B1 (enExample)
JP (1) JP6023061B2 (enExample)
CN (1) CN103282378B (enExample)
AU (1) AU2011311946B8 (enExample)
CA (1) CA2813752A1 (enExample)
WO (1) WO2012048115A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048115A2 (en) 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
JP7356911B2 (ja) 2017-06-14 2023-10-05 ヴァイロメティックス アーゲー 呼吸器合胞体ウイルスに対する予防のための環状ペプチド
CA3121724A1 (en) 2018-12-20 2020-06-25 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
CN110853704B (zh) * 2019-11-11 2020-11-06 腾讯科技（深圳）有限公司 蛋白质数据获取方法、装置、计算机设备及存储介质

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
WO2002102303A2 (en) 2001-05-01 2002-12-27 Medimmune, Inc. Crystals and structure of synagis fab
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US20100068217A1 (en) 2006-08-25 2010-03-18 Kwong Peter D Epitope-transplant scaffolds and their use
US8563002B2 (en) * 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
WO2009100376A2 (en) 2008-02-07 2009-08-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antigenic cloaking and its use
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
WO2012048115A2 (en) 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
US9701720B2 (en) 2012-04-05 2017-07-11 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogens against respiratory syncytial virus (RSV)

Also Published As

Publication number Publication date
WO2012048115A3 (en) 2012-06-21
JP2014502143A (ja) 2014-01-30
EP2625194B1 (en) 2015-08-12
AU2011311946B2 (en) 2014-10-02
US9718862B2 (en) 2017-08-01
CN103282378B (zh) 2015-03-11
AU2011311946A1 (en) 2013-05-02
WO2012048115A2 (en) 2012-04-12
CA2813752A1 (en) 2012-04-12
US20130280262A1 (en) 2013-10-24
EP2625194A2 (en) 2013-08-14
AU2011311946B8 (en) 2014-10-09
CN103282378A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
EP3054971B1 (en) Epstein-barr virus vaccines
TWI663175B (zh) 穩定化可溶性融合前ｒｓｖ ｆ多肽
JP2024160321A (ja) パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
CN103282378B (zh) 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途
CN111848753A (zh) 新型冠状病毒抗原表位及其应用
WO2022184027A1 (zh) 一种新型冠状病毒多价抗原、其制备方法和应用
WO2023186170A1 (zh) 一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用
EP2834263B9 (en) Epitope-scaffold immunogens against respiratory syncytial virusm (rsv)
EP2238160B1 (en) Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof
JP2009022186A (ja) 抗原ペプチドおよびその利用
CN110551187A (zh) 化学合成的h7n9禽流感病毒na蛋白胞外区抗原片段及制备方法和应用
CN116209672A (zh) Sars-cov-2抑制剂
WO2023217005A1 (zh) 串联式杂合三聚体新冠疫苗
WO2014152946A2 (en) Polypeptides for treating and/or limiting influenza infection
WO2022232648A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
WO2024199469A1 (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
JP4446887B2 (ja) オオアワガエリ花粉アレルゲンＰｈｌＰ７に基づく低アレルゲン性アレルギーワクチン
US20240262869A1 (en) POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF
WO2013152169A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection
US10766929B2 (en) De novo designed hemagglutinin binding proteins
WO2018175518A1 (en) Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
WO2023138648A1 (zh) SARS-CoV-2刺突蛋白变体、其药物组合物及用途
CN106749672B (zh) 一种丙型肝炎病毒融合抗原蛋白及其应用
AU2024347309A1 (en) Reagents and methods for preventing, treating or limiting henipavirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161006

R150 Certificate of patent or registration of utility model

Ref document number: 6023061

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees